Related Experiment Video
Updated: Aug 5, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Systemic and regional hemodynamic effects of gallopamil in patients with essential hypertension
R G Ketelhut1, F H Messerli, C Losem
1Medizinische Poliklinik, Universitäts-Klinikum Charité, Berlin, Germany.
Insights
Gallopamil effectively lowers blood pressure and vascular resistance in hypertensive patients. This essential hypertension treatment did not cause fluid retention or lasting heart rate changes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Essential hypertension is a prevalent cardiovascular condition.
- Managing blood pressure while avoiding adverse hemodynamic effects is crucial.
Purpose of the Study:
- To evaluate the hemodynamic effects of gallopamil in patients with essential hypertension.
- To assess the impact of gallopamil on systemic and regional hemodynamics.
Main Methods:
- Hemodynamic parameters were measured in 10 hypertensive patients before and during gallopamil therapy.
- Cardiac output was determined using indocyanine dye; plasma volume and renal blood flow were measured radioisotopically.
Main Results:
- An initial dose of slow-release gallopamil reduced arterial pressure and total peripheral resistance, with a transient increase in heart rate and cardiac output.
- Sustained gallopamil treatment (8-12 weeks) maintained reduced arterial pressure and peripheral resistance without altering heart rate or cardiac output.
- Gallopamil significantly decreased renal and splanchnic vascular resistance, without affecting plasma or total blood volume.
Conclusions:
- Gallopamil effectively reduces arterial pressure and vascular resistance in essential hypertension.
- The antihypertensive effect of gallopamil is achieved without significant fluid retention or prolonged reflex cardiovascular stimulation.
Abstract:
Systemic and regional hemodynamics were assessed in 10 patients with uncomplicated mild to moderate essential hypertension before and during gallopamil therapy. Cardiac output was measured in triplicate with indocyanine dye. Plasma volume and renal blood flow were measured radioisotopically. Immediately following the initial dose of a slow-release (SR) formulation of gallopamil, a significant fall in arterial pressure associated with a decreased total peripheral resistance and a reflex increase in heart rate and cardiac output were seen. Then, after 8-12 weeks of treatment, arterial pressure and total peripheral resistance remained reduced, but heart rate and cardiac output returned to pretreatment levels. Gallopamil also produced significant reductions in renal and splanchnic vascular resistance. Plasma volume and total blood volume did not change. Thus, gallopamil reduced arterial pressure and vascular resistances without fluid retention or prolonged reflexive changes.
More Related Videos
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies

